

**AMENDMENTS TO THE SPECIFICATION:**

Please amend the specification as follows:

Page 4, line 22 to page 5, line 7:

In addition, 5-HT<sub>7</sub> receptor antagonistic compounds having selective binding affinity for 5-HT<sub>7</sub> receptor (to be referred to as 5-HT<sub>7</sub> selective antagonistic compounds hereinafter) have been known, such as DR-4004 (*J. Med. Chem.* (1999) 42, 533), SB-269970 (*J. Med. Chem.* (2000) 43, 342 - 345), SB-691673 (*Bioorg. Med. Chem. Lett.* (2003) 13, 1055 - 1058), an aminotriazole derivative (*Bioorg. Med. Chem. Lett.* (2004) 14, 4245 - 4248)), an aminotetralin derivative (*J. Med. Chem.* (2004) 47, 3927 - 3930), an aminochroman derivative (*J. Med. Chem.* (2004) 47, 3927 - 3930), a 11-phenyapomorphine derivative (*J. Med. Chem.* (2001) 44, 1337 - 1340), and the like.

Page 7, lines 12-16:

~~As described in the foregoing, great concern has been directed toward a prophylactic antimigraine agent having excellent effect to prevent migraine and in which the side effects found in the existing prophylactic antimigraine agents are reduced.~~

Page 36, line 18, to page 37, line 7:

In this connection, affinities of each of RS-127445 (2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine; see WO 97/44326 for its production method) and SB-269970 ((R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol; see WO

97/48681 for its production method) described in the following test method (4) for respective receptors are conventionally known, and regarding the RS-127445, it has been reported that said compound has a pKi value of 9.5 for 5-HT<sub>2B</sub> receptor, and is 1000 times more 5-HT<sub>2B</sub> receptor selective against 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>,  $\alpha_1$ , M<sub>1</sub> and D<sub>2</sub> receptors. Also, regarding the SB-269970, it has been reported, for example in *J. Med. Chem.* (2000) 43, 342 – 345, that said compound has a pKi value of 8.9 for [[5-HT<sub>2B</sub>]] 5-HT<sub>7</sub> receptor, and is 250 times more 5-HT<sub>7</sub> receptor selective against 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>4</sub>, 5-HT<sub>6</sub>,  $\alpha_1$  and D<sub>2</sub> receptors.

Page 54, line 20 to page 55, line 2:

2-Fluoro-4'-methyl-6-nitrobiphenyl [FAB-MS: 232 (M + H)<sup>+</sup>] was obtained from 2-fluoro-6-nitrophenyl trifluoromethanesulfonate and 4-methylphenylboric acid by carrying out the reaction in the same manner as in Reference Example 1-a, and converted into (6-fluoro-4'-methylbiphenyl-2-yl)amine [EI-MS: 201 (M)<sup>+</sup>] by subjecting this nitro group to catalytic hydrogenation reduction, and then Sandmeyer reaction was carried out to obtain 2-bromo-6-fluoro-4'-methylbiphenyl. EI-MS: 266 (M)<sup>+</sup>, [[268(M)<sup>+</sup>]] 268 (M+2)<sup>+</sup>.